Circulating miR-21 as a potential biomarker in human digestive system carcinoma: a systematic review and diagnostic meta-analysis

Aalami, Amir Hossein; Abdeahad, Hossein; Mesgari, Mohammad

doi:10.1080/1354750x.2021.1875504

Cited by 17 publications

(8 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MicroRNAs (miRs) are small 18-25 nucleotide long nonprotein-coding RNAs that regulate gene expression by pairing to the 3′ untranslated region of their target mRNAs in body fluids as free circulating miRs [ 54 – 56 ]. Urinary miRs can be derived from various specimens—voided urine, urine sediment, or supernatant [ 57 ].…”

Section: Discussionmentioning

confidence: 99%

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

Aalami

Abdeahad

Mesgari

et al. 2021

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Aims. Bladder cancer (BCa) is a common cancer in North America and Europe that carries considerable morbidity and mortality. A reliable biomarker for early detection of the bladder is crucial for improving the prognosis of BCA. In this meta-analysis, we examine the diagnostic role of the angiogenin (ANG) protein in patients’ urine with bladder neoplasm. Methods. We performed a systematic literature search using ScienceDirect, Web of Science, PubMed/MEDLINE, Scopus, Google Scholar, and Embase, up to 10th October 2020 databases. Meta-Disc V.1.4 and Comprehensive Meta-Analysis V.2.2 software calculated the pooled specificity, sensitivity, area under the curve (AUC), diagnostic odds ratio (DOR), positive likelihood ratio (LR+), negative likelihood ratio (LR-), Q ∗ index, and summary receiver-operating characteristic (SROC) for the role of ANG as a urinary biomarker for BCa patients. Results. Four case-control studies were included with 656 participants (417 cases and 239 controls) in this meta-analysis. The pooled sensitivity of 0.71 (95% CI: 0.66–0.75), specificity of 0.78 (95% CI: 0.73–0.81), LR+ of 3.34 (95% CI: 2.02–5.53), LR- of 0.37 (95% CI: 0.32–0.44), DOR of 9.99 (95% CI: 4.69–21.28), and AUC of 0.789 and Q ∗ index of 0.726 demonstrate acceptable diagnostic precision of ANG in identifying BCa. Conclusion. This meta-analysis showed that ANG could be a fair biomarker for the diagnosis of BCa patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

Aalami

Abdeahad

Mesgari

et al. 2021

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our comparison of the results of studies in the Chinese population with investigations conducted in other populations showed that, regardless of the methodology, salivary biomarkers can be used efficiently and effectively to diagnose BC in Chinese patients. Some studies have reported that biomarker accuracy in the Chinese population is different from other countries 71,72 …”

Section: Discussionmentioning

confidence: 99%

“…Some studies have reported that biomarker accuracy in the Chinese population is different from other countries. 71 , 72 …”

Section: Discussionmentioning

confidence: 99%

“…Some studies have reported that biomarker accuracy in the Chinese population is different from other countries. 71,72 Although a number of systematic reviews have examined the utility of saliva in the diagnosis of oral, head, and neck malignancies, [73][74][75][76][77][78][79] limited review studies on the use of salivary biomarkers for diagnosis of distant cancers, especially BC are available. 54 To the best of our knowledge, this is the first systematic review and meta-analysis evaluating the potential of salivary biomarkers in the diagnosis of BC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Salivary biomarkers in breast cancer diagnosis: A systematic review and diagnostic meta‐analysis

et al. 2022

View full text Add to dashboard Cite

Background Salivary diagnostics and their utility as a nonaggressive approach for breast cancer diagnosis have been extensively studied in recent years. This meta‐analysis assesses the diagnostic value of salivary biomarkers in differentiating between patients with breast cancer and controls. Methods We conducted a meta‐analysis and systematic review of studies related to salivary diagnostics published in PubMed, EMBASE, Scopus, Ovid, Science Direct, Web of Science (WOS), and Google Scholar. The articles were chosen utilizing inclusion and exclusion criteria, as well as assessing their quality. Specificity and sensitivity, along with negative and positive likelihood ratios (NLR and PLR) and diagnostic odds ratio (DOR), were calculated based on random‐ or fixed‐effects model. Area under the curve (AUC) and summary receiver‐operating characteristic (SROC) were plotted and evaluated, and Fagan's Nomogram was evaluated for clinical utility. Results Our systematic review and meta‐analysis included 14 papers containing 121 study units with 8639 adult subjects (4149 breast cancer patients and 4490 controls without cancer). The pooled specificity and sensitivity were 0.727 (95% CI: 0.713–0.740) and 0.717 (95% CI: 0.703–0.730), respectively. The pooled NLR and PLR were 0.396 (95% CI: 0.364–0.432) and 2.597 (95% CI: 2.389–2.824), respectively. The pooled DOR was 7.837 (95% CI: 6.624–9.277), with the AUC equal to 0.801. The Fagan's nomogram showed post‐test probabilities of 28% and 72% for negative and positive outcomes, respectively. We also conducted subgroup analyses to determine specificity, sensitivity, DOR, PLR, and NLR based on the mean age of patients (≤52 or >52 years old), saliva type (stimulated and unstimulated saliva), biomarker measurement method (mass spectrometry [MS] and non‐MS measurement methods), sample size (≤55 or >55), biomarker type (proteomics, metabolomics, transcriptomics and proteomics, and reagent‐free biophotonic), and nations. Conclusion Saliva, as a noninvasive biomarker, has the potential to accurately differentiate breast cancer patients from healthy controls.

show abstract

“…To date, several investigations have focused on the biological functions of miR-21 across human cancers [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ]. However, few reviews have been published in the interim, failing to provide a broad view of the topic.…”

Section: Introductionmentioning

confidence: 99%

MiR-21 in the Cancers of the Digestive System and Its Potential Role as a Diagnostic, Predictive, and Therapeutic Biomarker

Nguyen

Kacimi

Nguyen

et al. 2021

Biology

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNAs. They can regulate the expression of their target genes, and thus, their dysregulation significantly contributes to the development of cancer. Growing evidence suggests that miRNAs could be used as cancer biomarkers. As an oncogenic miRNA, the roles of miR-21 as a diagnostic and prognostic biomarker, and its therapeutic applications have been extensively studied. In this review, the roles of miR-21 are first demonstrated via its different molecular networks. Then, a comprehensive review on the potential targets and the current applications as a diagnostic and prognostic cancer biomarker and the therapeutic roles of miR-21 in six different cancers in the digestive system is provided. Lastly, a brief discussion on the challenges for the use of miR-21 as a therapeutic tool for these cancers is added.

show abstract

Circulating miR-21 as a potential biomarker in human digestive system carcinoma: a systematic review and diagnostic meta-analysis

Cited by 17 publications

References 53 publications

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis

Salivary biomarkers in breast cancer diagnosis: A systematic review and diagnostic meta‐analysis

MiR-21 in the Cancers of the Digestive System and Its Potential Role as a Diagnostic, Predictive, and Therapeutic Biomarker

Contact Info

Product

Resources

About